Oculometry as an Attentional Mechanism Evaluation Tool and Attention Deficit Hyperactivity Inhibition (TDAH)

The aim of this study is to analyse thanks to eye tracking experiments ocular movement classical parameters in children with attention deficit hyperactivity (ADH) and to compare them to results obtained in healthy children and to results obtained with neuropsychological tests commonly used in standard health care. We should then be able to compare eye tracking with neuropsychological parameters. The final objective is to give to health professional a tool for ADH investigation with which they should be able to do a simple and effective follow up of children with ADH.

Condition or disease

<table>
<thead>
<tr>
<th>Condition or disease</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attention Deficit-Hyperactivity</td>
<td>Behavioral: Neuropsychological testsBehavioral: Oculometric tests</td>
</tr>
</tbody>
</table>

Study Design

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Interventional (Clinical Trial)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated Enrollment</td>
<td>60 participants</td>
</tr>
<tr>
<td>Intervention Model</td>
<td>Single Group Assignment</td>
</tr>
<tr>
<td>Masking</td>
<td>None (Open Label)</td>
</tr>
</tbody>
</table>
Primary Purpose: Supportive Care

Official Title: Oculometry as an Attentional Mechanism Evaluation Tool and Attention Deficit Hyperactivity Inhibition

Actual Study Start Date: May 5, 2014

Estimated Primary Completion Date: December 31, 2018

Estimated Study Completion Date: December 31, 2018

Resource links provided by the National Library of Medicine
MedlinePlus related topics: Attention Deficit Hyperactivity Disorder

U.S. FDA Resources

Arms and Interventions

<table>
<thead>
<tr>
<th>Arm</th>
<th>Intervention/treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental: Oculometric and neuropsychological tests</td>
<td>Behavioral: Neuropsychological tests</td>
</tr>
<tr>
<td>Oculometric tests and neuropsychological tests</td>
<td>WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test</td>
</tr>
<tr>
<td>Behavioral: Oculometric tests</td>
<td>When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.</td>
</tr>
</tbody>
</table>

Outcome Measures

Primary Outcome Measures:

1. Correlation between oculometric and neuropsychological tests in ADH evaluation [ Time Frame: Day 1 ]

   Differentiation between simple oculomotor disorder and attentional-visual disorder

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study: 8 Years to 12 Years (Child)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- Children between 8 and 12 years old
- Boys and girls
• DSM-IV-TR diagnostic criteria for ADH
• Children with methylprednisone treatment
• Social security affiliation
• signed informed consent

Exclusion Criteria:
• specialised scholarship
• refusal from children or parents
• too law results in WISC test (pre-inclusion test)

Contacts and Locations
Go to ▼

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): **NCT03546010**

Contacts

Contact: Annie Laurent, MD 04 76 76 54 19 AnnieLaurent@chu-grenoble.fr
Contact: Nathalie Guyader, MCD UJF 04 76 57 43 72 nathalie.guyader@gipsa-lab.grenoble-inp.fr

Locations

France

Grenoble Alps Hospital Recruiting
Grenoble, France
Contact: Annie Laurent, MD

Sponsors and Collaborators
University Hospital, Grenoble

Investigators

Principal Investigator: Annie Laurent, MD Grenoble Alps University Hospital

More Information
Go to ▼

Publications:

Responsible Party: University Hospital, Grenoble
ClinicalTrials.gov Identifier: **NCT03546010** History of Changes
Other Study ID Numbers: 38RC14.100
First Posted: June 5, 2018 Key Record Dates
Last Update Posted: June 5, 2018
Last Verified: June 2018

Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders

Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms